IMT 009
Alternative Names: IMT-009Latest Information Update: 28 Mar 2025
At a glance
- Originator Immunitas Therapeutics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Natural killer cell modulators; NK cell lectin-like receptor subfamily B inhibitors; T lymphocyte modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Lymphoma; Solid tumours
- No development reported Glioma
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for preclinical development in Glioma in USA (Parenteral)
- 10 Apr 2024 Interim pharmacodynamics data from a preclinical studies in Solid tumours and Lymphoma released by (Company)
- 05 Apr 2024 Pharmacodynamics data from a preclinical studies in Solid tumours and Lymphoma presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)